Q1 FY2027 · ended Aug 31, 2026 · Revenue $222.80M, +6.5% YoY · Filed Oct 7, 2026
Neogen Corporation (NEOG) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In Q1 of fiscal 2027, the quarter ended Aug 31, 2026, it reported revenue of $222.8 million and a net loss of $11.9 million. Free cash flow was $4.7 million. As of Aug 31, 2026 it held $172.0 million in cash and investments and $774.2 million in total debt.
Revenue
$222.80M
+6.5% vs year-ago quarter
Net income
$-11.90M
-132.8% vs year-ago quarter
Operating cash flow
$12.90M
+19.4% vs year-ago quarter
Free cash flow
$4.70M
+135.6% vs year-ago quarter
EPS
$-0.05
-129.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
218.31M
+0.5% vs year-ago quarter
Net cash
$-602.20M
Q1 FY2027
Operating margin
-0.8%
TTM
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- NEOG (Nasdaq)
- Fiscal year ends
- May 31
- Incorporated in
- MI
- Headquarters
- Lansing, MI
- SEC filer status
- Large accelerated filer
- SEC CIK
- 711377
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Aug 31, 2026 |
Q4 FY2026 May 31, 2026 |
Q3 FY2026 Feb 28, 2026 |
Q2 FY2026 Nov 30, 2025 |
Q1 FY2026 Aug 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $222.8M | $225.3M | $211.2M | $224.7M | $209.2M |
| Operating income | -$1.8M | $3.1M | -$3.3M | -$5.4M | -$16.1M |
| Net income | -$11.9M | -$11.3M | -$17.0M | -$15.9M | $36.3M |
| Diluted EPS | -$0.05 | -$0.05 | -$0.08 | -$0.07 | $0.17 |
| Operating cash flow | $12.9M | $30.2M | $22.7M | $19.5M | $10.8M |
| Free cash flow | $4.7M | $26.2M | $11.1M | $7.8M | -$13.2M |
| Total assets | $3.3B | $3.3B | $3.4B | $3.4B | $3.4B |
| Total liabilities | $1.2B | $1.3B | $1.3B | $1.3B | $1.3B |
| Stockholders' equity | $2.1B | $2.1B | $2.1B | $2.1B | $2.1B |
| Cash and investments | $172.0M | $185.5M | $159.9M | $145.3M | $138.9M |
| Total debt | $774.2M | $812.7M | $793.3M | $792.9M | $792.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Oct 26, 2026 | Oct 1, 2026 |
| 10-Q | Quarterly report | Oct 7, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 7, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 6, 2026 | Oct 6, 2026 |
| ARS | Annual report to shareholders | Aug 21, 2026 | May 31, 2026 |
All 1000 Neogen Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.